Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (EXCELLENT Study)

Ruijin Hospital0 个研究点目标入组 1,000 人开始时间: 2026年6月1日最近更新: 2026年6月18日

适应症

试验速览

阶段: 不适用
状态: 尚未招募
发起方: Ruijin Hospital
入组人数: 1,000

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.

详细描述

Peripheral T-cell lymphoma (PTCL）is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for ~10%. Patients with PTCL still have poor treatment response and prognosis under conventional CHOP regimen. This multi-center, prospective, registry study is designed to analyze the clinical characteristics and prognosis of different molecular subtypes of PTCL. The results can guide future precision therapy for PTCL.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2026 to December 2029 and detected by gene sequencing (NGS) with different molecular subtypes.
•Patients diagnosed with PTCL by histopathology from January 2026 to June 2026 and NGS detection can be performed if there is tumor tissue.
•Fully understand the study, voluntarily sign the written informed consent form (ICF), and agree to cooperate with genetic testing, treatment, efficacy assessment and long-term follow-up.
•Age ≥ 18 years

排除标准

•Female patients who are pregnant, breastfeeding, or of childbearing potential without effective contraception;
•Subjects with poorly controlled neurological, psychiatric, mental or cognitive disorders that may impair their understanding and signing of the informed consent form as well as adherence to the study procedures;
•Any other conditions deemed inappropriate for enrollment by the investigator.

研究者

发起方

Ruijin Hospital

申办方类型

Other

责任方

Principal Investigator

主要研究者

Zhao Weili

Vice president of Ruijin Hospital

Ruijin Hospital

相似试验

招募中

不适用

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)Peripheral T Cell Lymphoma

NCT05934864Ruijin Hospital1,000

尚未招募

2 期

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell LymphomaPeripheral T-Cell Lymphoma (PTCL NOS)Nodal T-follicular Helper Cell LymphomaAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)

NCT07535762Shanghai Jiao Tong University School of Medicine36

尚未招募

1 期

TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

NCT07342738Sun Yat-sen University25

尚未招募

1 期

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell LymphomaCutaneous T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma, RelapsedSezary SyndromeCutaneous T Cell Lymphoma (CTCL)

NCT07535710Shanghai Jiao Tong University School of Medicine37

Enrolling By Invitation

3 期

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680N.N. Petrov National Medical Research Center of Oncology114